$MSTX Up to date company activities and other important

New Post Public Reply Private Reply Replies (0) Message Board

Jun 25, 2014 at 10:14 AM

$MSTX Up to date company activities and other important information about $MSTX

$MSTX

DD Notes ~ http://www.ddnotesmaker.com/MSTX

##### recent news/filings ~ source: finance.yahoo.com

Tue, 24 Jun 2014 14:19:22 GMT ~ Mast Therapeutics' MST-188 Would Fit Well In Merck's Drug Development Pipeline
read full: http://seekingalpha.com/article/2283763-mast-...urce=yahoo
*********************************************************

Fri, 20 Jun 2014 20:31:40 GMT ~ MAST THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vot
read full: http://biz.yahoo.com/e/140620/mstx8-k.html
*********************************************************

Thu, 19 Jun 2014 20:15:00 GMT ~ Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
- SAN DIEGO, June 19, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. "We are delighted to welcome Howard to the Board," stated Jack Lief, Chair of Mast's Board of Directors. "His medical training and extensive clinical development and regulatory affairs experience, particularly with cardiovascular agents, is highly relevant to Mast's development programs and will enrich our expertise. We look forward to benefitting from his contributions and insights." Dr. Dittrich currently serves as Chief Medical Officer of Sorbent Therapeutics, a privately-held biopharmaceutical company developing therapies for cardiovascular and renal diseases, a position he has held since February 2012. Previously, from June 2003 until it was acquired by Merck & Co., Inc. in September 2007, Dr. Dittrich served as Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs of NovaCardia, Inc., a clinical-stage pharmaceutical company focused on cardiovascular diseases, and, from September 2007 to June 2011, he co-founded and served as Chief Medical Officer of Sequel Pharmaceuticals, Inc., a privately-held pharmaceutical company spun out from NovaCardia following its acquisition by Merck. Prior to NovaCardia, from 1996 to 2002, Dr. Dittrich held executive positions overseeing clinical development and regulatory affairs at Molecular Biosystems, Inc. and Alliance Pharmaceutical Corp., during which time he was instrumental in gaining U.S. Food and Drug Administration approval of two cardiovascular imaging agents. From 1984 to 1996, he was a full-time faculty member of the Department of Medicine at the University of California, San Diego (UCSD) and, from 1996 to 2011, he served part-time as Clinical Professor of Medicine at UCSD. Dr. Dittrich holds a B.S. d...
read full: http://finance.yahoo.com/news/mast-announces-...00262.html
*********************************************************

Mon, 16 Jun 2014 12:04:21 GMT ~ Mast Therapeutics initiates sub-study within Phase 3 EPIC trial
read full: http://www.theflyonthewall.com/permalinks/ent...EPIC-trial
*********************************************************

Mon, 16 Jun 2014 12:00:00 GMT ~ Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
- SAN DIEGO, June 16, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device. MST-188 has been shown to reduce viscosity and adhesive frictional forces in blood and improve microvascular blood flow. Improvements in the flow of oxygen-carrying blood to tissues and organs can be expected to improve tissue oxygenation, shorten the duration of vaso-occlusive crisis, and limit tissue damage and end-organ dysfunction and failure. Brian M. Culley, Chief Executive Officer, said: "Organ failure, which is the leading cause of premature death in adults with sickle cell disease, is thought to be the consequence of a lifetime of repeated vaso-occlusive events and the resulting ischemia. We believe that measuring effects on microvascular blood flow and tissue oxygenation during vaso-occlusive crisis will be useful to understanding MST-188's potential to improve long-term outcomes for sickle cell patients where multi-decade, survival trials are impractical. MST-188 has already demonstrated an ability to improve microvascular blood flow. Now, this sub-study will demonstrate whether MST-188 also improves tissue oxygenation. Together, these data will provide insight into the potential for MST-188 to reduce end-organ failure and associated premature death in individuals with sickle cell disease."
read full: http://finance.yahoo.com/news/mast-therapeuti...00240.html
*********************************************************

##### chart ~ source: stockcharts.com

stockcharts.com/c-sc/sc?s=MSTX&p=D&b=5&g=0&id=p95448242713

##### chart ~ source: eoddata.com

http://chart.eoddata.com/?e=OTCBB&s=MSTX&...D&b=BB

##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/MSTX/company-info
Ticker: $MSTX
OTC Market Place: Not Available
CIK code: 0001160308
Company name: Mast Therapeutics, Inc.
Company website: http://www.masttherapeutics.com
Incorporated In: DE, USA

##### extra dd links

Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/MSTX/filings
Latest financials: http://www.otcmarkets.com/stock/MSTX/financials
Latest news: http://www.otcmarkets.com/stock/MSTX/news - http://finance.yahoo.com/q/h?s=MSTX+Headlines

Major holdings: http://data.cnbc.com/quotes/MSTX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=MSTX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/MSTX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=MSTX

RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search

DTCC: http://search2.dtcc.com/?q=Mast+Therapeutics%...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.masttherapeutics.com
Alexa: http://www.alexa.com/siteinfo/http://www.mast...utics.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.masttherapeutics.com

Short Sales: http://www.otcmarkets.com/stock/MSTX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/MSTX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/MSTX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=MSTX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=MSTX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=MSTX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=MSTX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=MSTX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=MSTX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=MSTX
Balance Sheet: http://finance.yahoo.com/q/bs?s=MSTX
Cash Flow: http://finance.yahoo.com/q/cf?s=MSTX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/MSTX
Bloomberg: http://www.bloomberg.com/quote/MSTX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=MSTX
Bussinessweek: http://investing.businessweek.com/research/st...icker=MSTX
Barchart: http://www.barchart.com/quotes/stocks/MSTX
OTC Short Report: http://otcshortreport.com/index.php?index=MSTX
Investopedia: http://www.investopedia.com/markets/stocks/MSTX/?wa=0

http://www.pennystocktweets.com/stocks/profile/MSTX

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

##### business description ~ source: otcmarkets.com

DD Notes ~ http://www.ddnotesmaker.com/MSTX

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Geron Corp Faces Fiduciary Duty Investigation

Spotlight on Geron's Corporate Governance: What's Happening? The heat's been turned up on Geron Corporation this week, with Halper Sadeh LLC, an investor rights law outfit, digging into whether some folks at the helm have strayed from their fiduciary duties to the shareholders. Now, if you're holding onto NASDAQ:GERN stock or thinking about diving in, it's high time to...

PACS Group Faces Legal Scrutiny: What to Watch

PACS Group: Legal Storm Brewing Welcome to the latest saga in the volatile theater of corporate governance. PACS Group, Inc., ticker symbol NYSE:PACS, is under the microscope, and not for debuting a groundbreaking product or hitting a stock milestone. Nope, instead we've got Halper Sadeh LLC out of New York investigating some possible hanky-panky from PACS directors and...

HONA Faces Legal Heat: Investor Lawsuit Over Losses

The Investor Storm Brewing Over Honeywell Aerospace There it is again, another industry heavyweight caught in a dizzying whirlwind of litigation. Honeywell Aerospace Inc. (NASDAQ:HONA), a name as established as an old boot in the business, now faces a class action lawsuit that's got investors frantically dusting off phone numbers for their attorneys. The Messy Allegations...

AST SpaceMobile Faces Class Action Over Misstatements

What's Going On with AST SpaceMobile? Kicking off with a heavy hitter here, folks. AST SpaceMobile, Inc., trading under NASDAQ:ASTS, is under a securities fraud spotlight. We're talking allegations piled higher than a morning stack of pancakes. If you picked up any ASTS shares between March 4, 2025, and July 15, 2026, you're in on this rough ride. There's a class action...

Farm Aid 2026: A Resilient Tribute to Family Farmers

Shining a Light on Essential Family Farmers Every year, thousands gather for Farm Aid to back the unsung heroes who put food on our plates. In 2026, the scene shifted to the amphitheater at Virginia Beach, where an epic lineup of music took stage not just to entertain but to underline a critical issue—family farmers are fighting for survival. These folks aren't merely...

CVS Health Under Fire: Fiduciary Duty Breach?

CVS Under Regulatory Spotlight for Fiduciary Breaches You'd think by now companies would have their fiduciary ducks in a row. But here we are, with CVS Health Corporation (NYSE: CVS) catching heat from the legal eagles over at Halper Sadeh LLC. The knife’s out for some of the big wigs – apparently, there's chatter they might’ve slipped on their duty to play nice...

China Southern Airlines Marks 70th Anniversary in NYC

Taking Flight with Legacy and Tradition Throwing a bash on Times Square isn't just about flash; it's about letting folks know you mean business. And China Southern Airlines has been doing just that for 70 years. Imagine starting from Guangzhou and ending up splashed across New York City's giant LED screens—talk about a journey! From Humble Roots to Global Network...

Cut Winter Heating Costs with Townsend's Rebate Help

Unseen Perils of Winter Heating in Massachusetts Massachusetts homeowners, listen up. If your heating system is older than the Model T, it's time to rethink your winter strategy. You don't want to be stuck in the cold when the thermometer hits single digits, do you? That's where Townsend comes in, making waves with their rebate assistance program. Navigating the Rebate...

Quay Sunglasses: Luxury Looks, Affordable Prices

Ah, sunglasses—the quintessential accessory that screams both practicality and style. A million-dollar look without the million-dollar expense? That's where Quay comes in. They've been recognized by Expert Consumers, no less, as some of the best-in-class for affordable luxury eye candy out there—aimed at shoppers who want the designer vibe without the hemorrhaging...

AI and Storytelling Make Waves in Science Education

University's Innovative Approach to Learning Alright, here's something you don't see every day. The University of Phoenix managed to snag some kudos from an academic journal for using AI and storytelling to teach environmental science. That's like hitting two bulls-eyes with one shot in the world of education. The recognition from Glacies for this Editor's Choice paper...